Noninvasive liver fibrosis assessment in metabolic dysfunction-associated steatotic liver disease

Table 1 Steatotic liver disease nomenclature

Nomenclature	Definition
NAFLD	Nonalcoholic fatty liver disease is defined by the presence of ≥ 5% of macrovesicular steatosis and the absence of an identified alternative diagnosis, as well as a significant ongoing or recent alcohol consumption (defined as < 30 g/day for men and < 20 g/day for women)
NASH	Presence of inflammation and cellular injury expressed by ballooning
MAFLD	Presence of steatosis evidenced by histology, imaging, or blood biomarker in addition to one of the following criteria: Overweight/obesity, type 2 diabetes mellitus, or evidence of metabolic syndrome
SLD	Presence of steatosis diagnosed histologically or by imaging techniques
MASLD	Presence of SLD associated with at least one cardiometabolic risk factor and no other identified cause, alcohol consumption should be less than 20 g/day for women and 30 g/day for men, previously called NAFLD
MASH	Presence of MASLD and cellular inflammation and/or injury, previously mentioned as NASH
Met-ALD	Met-ALD was recently proposed, defined as the presence of SLD and alcohol consumption between 20-50 g/day in women and 30-60 g/day in men

MAFLD: Metabolic dysfunction-associated fatty liver disease; MASH: Metabolic steatohepatitis; MASLD: Metabolic steatotic liver disease; Met-ALD: Metabolic steatotic liver disease with moderate alcohol consumption; NAFLD: Nonalcoholic liver disease; NASH: Nonalcoholic steatohepatitis; SLD: Steatotic liver disease.